ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the context of the imatinib suspension and validation (ISAV) study (NCT01578213), ddPCR was able to detect one BCR–ABL1 positive cell out of 107 cells, predicting relapse in CML patients after imatinib discontinuation [13].